Kwality Pharmaceuticals Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

- Fy27 revenue guidance: INR700+ crores with 26%-27% EBITDA margins. - Expected 25%-30% year-on-year revenue growth through FY30, targeting INR1,500 crore revenue by FY30. - EBITDA margins expected to improve gradually from ~27% in FY27 to 30% by FY29. - Hormone and biologics revenue not included in current guidance; could add INR150-200 crores (hormone) and INR400 crores (biologics) by FY29, potentially pushing revenue beyond INR1,500 crores. - Margin expansion possible, but biosimilars may see price pressures; overall margin trajectory remains positive. - Operating costs expected to be stable, facilitating margin improvement. - Cash flow sufficient for capex without additional debt; capex focused on hormone, oncology expansion, and biosimilar clinical trials. Overall, the company targets doubling revenues by FY30 with improving profitability and expanding EBITDA margins to around 30%.

The transcript provided does not explicitly mention the current or expected orderbook or pending orders for Kwality Pharmaceuticals Limited. However, relevant information that can infer business outlook includes: - Kwality is actively registering 6-7 new products per quarter across multiple regions (Mexico, Colombia, Chile, MENA, Saudi Arabia, GCC), indicating an expanding product pipeline. - Sales revenue guidance is strong, expecting INR700+ crores in FY27 with targeted growth of ~25%-30% annually, potentially reaching INR1,500 crores by FY30. - The company has multiple capex plans underway (hormone plant, oncology expansion, biologics clinical trials) supporting future order fulfillment capabilities. - Payments and receivables are stabilizing with debtor days expected to reduce from over 200 to ~165 days by FY27-end, improving working capital cycles. No explicit backlog or orderbook size is provided in the transcript.